Associated Papers
Integrating evidence from protein domains to identify cancer driver mutations.
Ostroverkhova D et al.
Protein Science : a Publication of the Protein Society, 2026
41556616 (PubMed )
Supplement: PRO-35-e70422-s002.xlsx › Table_S1
Patient-derived rhabdomyosarcoma cells recapitulate the genetic and transcriptomic landscapes of primary tumors.
Hu Y et al.
Iscience, 2024
39319271 (PubMed )
Supplement: mmc5.xlsx › Table_S4
An Analysis of Genetic Polymorphisms in 76 Genes Related to the Development of Ovarian Tumors of Different Aggressiveness.
Szafron LA et al.
International Journal of Molecular Sciences, 2024
39456660 (PubMed )
Supplement: ijms-25-10876-s001.zip › Supplement-variants.xlsx › Hot.spot.panel.SNP_all_variants
Standing in the canine precision medicine knowledge gap: Improving annotation of canine cancer genomic biomarkers through systematic comparative analysis of human cancer mutations in COSMIC.
Sakthikumar S et al.
Veterinary and Comparative Oncology, 2023
37248814 (PubMed )
Supplement: supplement_1.xlsx › Supp._Table_5
Clinical significance of FBXW7 loss of function in human cancers.
Fan J et al.
Molecular Cancer, 2022
Global and context-specific transcriptional consequences of oncogenic Fbw7 mutations.
Thirimanne HN et al.
Elife, 2022
35225231 (PubMed )
Supplement: elife-74338-fig5-data2.xlsx › Fbw7_Mutant
A genetically defined signature of responsiveness to erlotinib in early-stage pancreatic cancer patients: Results from the CONKO-005 trial.
Hoyer K et al.
Ebiomedicine, 2021
33862582 (PubMed )
Supplement: mmc3.xlsx › S5
FBXW7 mutation analysis and its correlation with clinicopathological features and prognosis in colorectal cancer patients.
Chang CC et al.
The International Journal of Biological Markers, 2015
Select a paper to view details